CLINICAL_TRIALS
trial_result
· 2014-04-02
Clinical Trial Update: GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment [Phase 1]
Summary
A Phase 1 study evaluating GDC-0449 (vismodegib) in young patients with recurrent or treatment-refractory medulloblastoma has been completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Childhood Medulloblastoma | Phase 1 | Status: COMPLETED